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Abstract
Background: The aim of this study was to examine the relationship between trends in CD4 counts (slope) and HIV
viral load (VL) after initiation of combination antiretroviral treatment (cART) in Asian patients in The TREAT Asia HIV
Observational Database (TAHOD).
Methods: Treatment-naive HIV-infected patients who started cART with three or more and had three or more CD4
count and HIV VL tests were included. CD4 count slopes were expressed as changes of cells per microliter per year.
Predictors of CD4 count slopes from 6 months after initiation were assessed by random-effects linear regression
models.
Results: A total of 1676 patients (74% male) were included. The median time on cART was 4.2 years (IQR 2.5-5.8
years). In the final model, CD4 count slope was associated with age, concurrent HIV VL and CD4 count, disease
stage, hepatitis B or C co-infection, and time since cART initiation. CD4 count continues to increase with HIV VL up
to 20 000 copies/mL during 6-12 months after cART initiation. However, the HIV VL has to be controlled below
5 000, 4 000 and 500 copies/mL for the CD4 count slope to remain above 20 cells/microliter per year during 12-18,
18-24, and beyond 24 months after cART initiation.
Conclusions: After cART initiation, CD4 counts continued to increase even when the concurrent HIV VL was
detectable. However, HIV VL needed to be controlled at a lower level to maintain a positive CD4 count slope
when cART continues. The effect on long-term outcomes through the possible development of HIV drug resistance
remains uncertain.
Background
Studies show that latent infection of CD4 cells provides
a mechanism for lifelong persistence of HIV-1, even in
patients on effective anti-retroviral therapy [1]. To sup-
press viral replication so that the VL is below the level
of detection with standard assays is thus one of the aims
at the start of antiretroviral treatment. Maximal and
durable suppression of HIV VL prevents or delays devel-
opment of drug resistant mutations, preserves CD4 cells,
and eventually results in better clinical outcomes.
According to the US guidelines, if HIV VL suppression
is not achieved, it is necessary to change to a new regi-
men, a second or third line regimen, with at least two
active drugs [2].
HIV-infected patients in most developing countries
have limited second and third line antiretroviral treat-
ment options [3]. In many countries in Asia, second-line
combination antiretroviral treatment (cART) is not
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widely accessible [4-6]. There remains some uncertainty
about the short-term risks to patients receiving first line
cART, in particular how their immune status might
deteriorate if they persist with a virologically failing regi-
men. The Pursuing Later Treatment Options (PLATO)
collaboration [7] reported that in patients experiencing
triple class failure, treatment regimens that maintain the
VL below 10 000 copies/mL or at least provide 1.5
log10 copies/mL suppression below the off-treatment
value do not seem to be associated with appreciable
CD4-cell-count decline. More recently, Mocroft et al [8]
also reported that CD4 did not significantly decrease
even HIV VL exceeded 10 000 copies/mL in patients
treated with regimen containing a boosted protease inhi-
bitor. The issue of when to switch from first line regi-
mens may therefore be difficult, especially for patients
with modest, stable HIV VL who are clinically doing
well [5,9].
The aims of this study were to examine the relationship
between trends in CD4 count and VL after initiation of
combination antiretroviral treatment in HIV-infected
Asian patients, using data from The TREAT Asia HIV
Observational Database (TAHOD).
Methods
Established in 2003, TAHOD is a collaborative observa-
tional cohort study involving 18 sites in the Asia-Pacific
region (See acknowledgement). Detailed methods are
published elsewhere [10]. Briefly, each site recruited
approximately 200-300 HIV-infected patients, including
both patients on or not initiating antiretroviral treat-
ment. Recruitment was based on a consecutive series of
patients regularly attending a given site from a particular
start-up time. Ethical approval for the study was
obtained from the University of New South Wales
Ethics Committee and respective local ethics committee.
The following data were collected: patient demo-
graphics and baseline data, CD4 and CD8 count, HIV
VL level, prior and new AIDS defining illness (ADI),
date and cause of death, prior and current prescribed
HAART, and reason for treatment change. Data are col-
lected according to a common protocol. Upon recruit-
ment, all available data prior to entry to TAHOD
(considered as retrospective data) are extracted from
patient case notes. Prospective data are updated six-
monthly at each clinic and transferred to data manage-
ment centre for aggregation and analyses. TAHOD sites
are encouraged to contact patients who were not seen
in the clinics in the previous 12 months.
TAHOD patients were included in this analysis if they
were treatment naïve and initiated with triple or more
combination antiretroviral treatment, and had three or
more concurrent CD4 and HIV VL test pairs (within
28 days if not tested on the same day) during follow-up.
Both retrospective and prospective data were included
in the analysis.
Trends in CD4 count (slope) was calculated by linear
regression with the values at time T, before T, and after
T, and was expressed as changes of cells per microliter
(μL) per year. The HIV VL was related to the CD4 count
slope at time T. Previous studies reported a two-phase
CD4 count response, demonstrated as a rapid increase
(a high CD4 count slope) in the first several months after
treatment initiation and followed by slower increase
(a smaller slope compared to the initial several months)
[11-14]. Preliminary analyses in eligible TAHOD patients
showed that the mean CD4 count slope was significantly
higher in the first 6 months after cART initiation
than in the period afterwards (179 vs. 44 cells/μL per
year, p < 0.001). The CD4 slopes were therefore calcu-
lated from CD4 counts measured 6 months after cART
initiation.
Predictors of the CD4 slope at time T was assessed by
random-effect linear regression models which take
account of within and between patient variability. Cov-
ariates included sex, age (per 10 years), disease stage
(CDC category A, tuberculosis with or without other
AIDS defining illness, other non-tuberculosis AIDS
defining illness), hepatitis coinfection (hepatitis B or C
antibody positive), haemoglobin level, time since cART
initiation, initial cART regimen non-nucleoside/nucleo-
tide reverse transcriptase inhibitor (NNRTI)-based, non-
boosted PI, or boosted PI, and treatment containing
abacavir. Disease stage, CD4 count and HIV VL were
fitted in the model as time-dependent variable. We did
not include CD4 count and HIV VL at baseline for the
following three reasons: first, a large proportion of
patients did not have the tests at treatment initiation
(approximately 25% of patients had no CD4 count and
45% HIV VL, Table 1); second, the model aimed to help
clinicians in this region to assess the status of immune
system with the clinical information at hand (e.g., age,
hepatitis status, current CD4 count, time since treat-
ment initiation, etc) where the baseline information on
CD4 count and HIV VL may not be readily available;
and third, when we included baseline CD4 and HIV VL
in a sensitivity analyses based on the subset of patients
with baseline data available, the results remained com-
parable with the model without the baseline CD4 count
and HIV VL. The multivariate models were built using a
forward-step approach, the final model included covari-
ates that remained significant at the 0.20 level. Non-
significant variables were also presented and adjusted
for in the final multivariate models.
To take into consideration of the treatment interrup-
tion and switch, the following sensitivity analyses were
performed: 1. restricting the records measured during
initial NNRTI-based regimen; 2. excluding the records
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measured when patients were off-treatment for more
than 30 days for various reasons. Finally, sensitivity ana-
lysis was also performed by restricting the records in
patients contributing at least 4 or more concurrent CD4
and HIV VL tests.
Data management and statistical analyses were per-
formed using SAS for Windows (SAS Institute Inc.,
Cary, NC, USA), and Stata (StataCorp, STATA 10.1 for
Windows, College Station, Texas 77845 USA).
Results
There were 4699 patients with data collected in TAHOD
as at September 2009. Approximately 75% of patients
had a clinic visit in the 12 months before September
2009, and 214 patients died since entry to TAHOD (mor-
tality 1.36 per 100 person years). Among the 4699
TAHOD patients, 612 were not currently receiving anti-
retroviral treatment, 31 were receiving mono or dual
therapy, and 4056 had initiated cART with three or more
drugs. 1676 naïve patients initiated cART, and had three
or more concurrent CD4 and HIV VL data pairs available
beyond 6 months after cART initiation.
Table 1 shows the patient characteristics at cART
initiation in patients included in the analysis and in all
TAHOD patients who initiated cART with three or
more drugs. The characteristics of the patients included
in the analysis are generally comparable to those of the
whole TAHOD patients, except that the patients
included were less likely to be anemic.
At cART initiation, the median age of the patients
included in the analysis was 36 years (interquartile
range, IQR, 30-42), median CD4 count 140 cells/μL
(IQR 42-230), median HIV VL 5.00 log10 copies/mL
(IQR 4.33-5.56), 12% had hepatitis B or C co-infection,
and 36% were diagnosed with an AIDS defining illness
(ADI). The median time on cART was 4.2 years (IQR
2.5 - 5.8). The median time between each CD4 and HIV
VL tests was 165 days (IQR 106 - 223). The initial
cART was predominantly an NNRTI-based regimen
(63% of 1676 patients in the analysis, with either nevira-
pine or efavirenz, plus two NRTI drugs, mostly stavu-
dine or zidovudine, plus lamivudine). Approximately
15% of the patients started a non-boosted PI (mostly
indinavir, nelfinavir or atanazavir) regimen with two
NRTI drugs and 20% started with a ritonavir-boosted PI
(mostly lopinavir, atanazavir or saquinavir). The annual
rate of a drug class change or change of at least two or
more drugs was approximately 20%. After cART initia-
tion, viral logical suppression (HIV VL < 400 copies/
mL) was achieved in 83% of patients at 6 month and
82% in 12 months.
Table 2 shows the random-effect linear regression
analysis of the CD4 count slope. Concurrent haemoglo-
bin level, initial cART containing NNRTI or boosted PI
were not significantly associated with the study endpoint
in both univariate and multivariate analyses. Initial
cART containing abacavir was significant in the univari-
ate analysis. In the final multivariate model, CD4 count
Table 1 Patient characteristics at baseline in patients selected in the analysis and patients starting 3 or more cART in
TAHOD
In analysis In TAHOD In analysis In TAHOD
Total patients 1676 4056 Haemoglobin (g/dL) at cART initiation
Age (year) at cART initiation Median (IQR) 14.0 (12.6, 15.2) 12.3 (10.8, 14.2)
Median (IQR) 36 (30, 42) 35 (30, 41) < 10 g/dL 27 (2%) 418 (16%)
<=30 437 (26%) 1188 (29%) 10+g/dL 1248 (98%) 2250 (84%)
31~40 748 (45%) 1814 (45%) Not tested 221 1388
41 or more 491 (29%) 1054 (26%) CD4 count (cells/μL) at cART initiation
Median (IQR) 140 (42, 230) 112 (37, 209)
Gender <=50 350 (28%) 990 (31%)
Male 1238 (74%) 2875 (71%) 51-100 155 (12%) 508 (16%)
Female 438 (26%) 1177 (29%) 101-200 328 (26%) 815 (26%)
Transgender 0 (0%) 4 (< 1%) 201-300 261 (21%) 551 (17%)
301 or more 161 (13%) 311 (10%)
CDC clinical classification for HIV infection at cART initiation Not tested 421 881
Stage A 980 (58%) 1984 (50%) HIV viral load (copies/ml) at cART initiation
Stage B 101 (6%) 407 (10%) Median log10 (IQR) 4.93 (4.22, 5.52) 4.94 (4.32, 5.51)
Stage C 595 (36%) 1665 (41%) < 500 101 (11%) 126 (9%)
501-10,000 80 (9%) 124 (9%)
Hepatitis B or C coinfection 10,001-50,000 173 (19%) 280 (20%)
No 1468 (88%) 3495 (86%) 50,001 or more 555 (61%) 885 (62%)
Yes 208 (12%) 566 (14%) Not tested 767 2641
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slope was associated with age (-4.8 cells/μL per year per
10-year age increase, p = 0.013), concurrent HIV VL
(-40.5 per 1 log10 copies/mL VL increase, p < 0.001),
concurrent CD4 count (+1.9 per 100 cells/μL increase),
disease stage (compared to CDC category A illnesses:
+26.3 if diagnosed with tuberculosis [TB] with or without
other ADI, p < 0.001; +12.0 if diagnosed with non-TB
ADI, p = 0.013), hepatitis B or C co-infection (-17.7 if co-
infected, p = 0.004), and time since cART initiation
(compared to CD4 slope during 6-12 months: -21.5 dur-
ing 12-18 months, p = 0.010; -25.8 during 18-24 months,
p = 0.002; -59.1 at 24 months or later, p < 0.001).
In Figure 1 we gave the formula obtained from Table 2
and an example to estimate the CD4 slope. The formula
needs the following information: current age, concurrent
CD4 count and HIV VL, hepatitis coinfection, disease
stage, and time since cART initiation.
The models shows that, after cART initiation, mean
CD4 counts continued to increase even when the con-
current HIV VL was detectable. In addition, the model
also shows that to maintain a positive CD4 count slope,
the HIV VL needed to be suppressed to a lower level in
later periods of cART. To illustrate, the estimated CD4
slopes from the model in two patients with specific
baseline characteristics are shown in Table 3 and in
Figure 2. The bold cells are when the estimated CD4
count slope falls between -20 and +20 cell/μL per year,
which we considered as indicative of borderline
CD4 count decreases. In the case of the first patient (aged
30 years, no hepatitis coinfection and AIDS defining
Table 2 Random-effect linear regression analyses of trend of CD4 count (slope, cells/μL per year)
Univariate Multivariate**
Difference* (95% CI) p value Difference* (95% CI) p value
Sex
Male* 0.0 0.0
Female 9.5 (0.1, 18.9) 0.047 7.8 (-1.5, 17.2) 0.099
Current age
per 10 years older -6.5 (-10.3, -2.7) 0.001 -4.8 (-8.6, -1.0) 0.013
Disease stage
CDC Category A* 0.0 0.0
TB with or without other ADI 24.4 (13.7, 35.1) < 0.001 26.3 (15.6, 37.0) < 0.001
Non-TB ADI(s) 3.7 (-5.6, 13.0) 0.433 12.0 (2.5, 21.4) 0.013
Haemglobin level
per 1 g/dL higher 0.0 (-0.0, 0.1) 0.661 0.0 (-0.0, 0.1) 0.689
Concurrent CD4 count
Per 100 cells/μL higher 1.3 (-0.3, 3.0) 0.116 1.9 (0.2, 3.7) 0.033
Concurrent viral load
per log10 copies/mL higher -40.9 (-48.7, -33.2) < 0.001 -40.5 (-48.4, -32.6) < 0.001
Hepatitis B or C coinfection
No* 0 0
Yes -19.1 (-31.1, -7.0) 0.002 -17.7 (-29.7, -5.7) 0.004
Time since cART initiation
> 6 to ≤ 12 months* 0.0 0.0
> 12 to ≤ 18 months -21.3 (-37.7, -5.0) 0.011 -21.5 (-37.8, -5.2) 0.010
> 18 to ≤ 24 months -23.1 (-39.3, -7.0) 0.005 -25.8 (-42.0, -9.7) 0.002
> 24 or more months -58.0 (-70.3, -45.7) < 0.001 -59.1 (-71.7, -46.5) < 0.001
Initial cART containing NNRTI
No* 0.0 0.0
Yes 6.4 (-1.4, 14.1) 0.106 -1.3 (-9.2, 6.6) 0.749
Initial cART containing boosted PI
No* 0.0 0.0
Yes -0.8 (-10.5, 9.0) 0.880 -3.4 (-13.2, 6.3) 0.493
Initial cART containing abacavir
No* 0.0
Yes -12.9 (-25.8, 0.0) 0.050 -5.6 (-18.5, 7.3) 0.397
* Difference were compared with the first category of each categorical variable.
** Constant term for multivariate model: 205.5 (174.4, 236.6) cells per μL per year.
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illness, and concurrent CD4 count 200 cells/μL), the CD4
count continues to increase with HIV VL up to 20 000
copies/mL during 6-12 months after cART initiation.
However, the HIV VL has to be controlled below 5 000, 4
000 and 500 copies/mL for the CD4 count slope to remain
on a safe level above 20 cells/μL/year during 12-18, 18-24,
and beyond 24 months after cART initiation.
Hepatitis co-infection had a significant effect on the
CD4 count slope. In one scenario, shown in Table 3 of
a 30-year old patient with concurrent CD4 count 200
cells/μL, no AIDS defining illness and no hepatitis coin-
fection, CD4 counts continues to increase with HIV VL
up to 5 000 copies/mL during 12-18 months after
cART. If this patient was hepatitis co-infected, the CD4
count starts to fall when the HIV VL increases up to
3 000 copies/mL.
The analyses were repeated in three subgroups as sen-
sitivity analysis (Table 4). The results are comparable to
the final model.
Discussion
In a subset of TAHOD patients who were treatment
naïve and initiated with three or more combination anti-
retroviral treatment and had concurrent CD4 count and
Information required:  
AGE: Current age (years) 
CD4: Concurrent CD4 count (cells/μL) 
VL: Concurrent HIV viral load (copies/mL) 
HEPATITIS: Hepatitis coinfection 
 1 = No  
 2 = Yes 
STAGE: Disease stage  
 1 = CDC category A 
 2 = TB with or without other ADI 
 3 = Non-TB ADI 
TIME: Time since initiation of combination antiretroviral treatment 
 1: >   6 to  12 months 
 2: > 12 to  18 months 
 3: > 18 to  24 months 
 4: > 24 or more months 
 
 
 
 
 
 
 
 
 
 
 
 
For example, if a patient is 30 years old (i.e. AGE = 30), concurrent CD4 250 cells/μL  
(i.e. CD4 = 250), HIV VL 5000 copies/mL (i.e. VL=5000), no coinfection  
(i.e. HEPATITIS = 1), no ADI (i.e. STAGE = 1), and started cART 15 months ago  
(i.e. TIME = 2), the estimated CD4 slope would then be:  
 
205.5 + (- 4.8) x (30/10) + (1.9) x (250 / 100) + (- 40.5) x (Log10 (5000))  
+ (0) + (0) + (- 21.5) = 24.5 cells/μL per year 
CD4 slope (cells/μL per year) 
= 205.5 + ( - 4.8) x (AGE/10) + (1.9) x (CD4/100) + ( - 40.5) x (Log10(VL))
0 if STAGE = 1
26.3 if STAGE = 2
12.0 if STAGE = 3
0 if TIME = 1
- 21.5 if TIME = 2
- 25.8 if TIME = 3
- 59.1 if TIME = 4
+ +
0 if HEPATITIS = 1
- 17.7 if HEPATITIS = 2
+
Figure 1 Estimating CD4 count slope.
Zhou et al. BMC Infectious Diseases 2010, 10:361
http://www.biomedcentral.com/1471-2334/10/361
Page 5 of 10
Table 3 Estimated CD4 slope (cells/μL/year) by duration of treatment and HIV VL.
Month since cART HIV VL level (copies/mL)
initiation 500 1 000 2 000 3 000 4 000 5 000 10 000 20 000 30 000 40 000 50 000 100 000 150 000
Patient 1, 30 years old, no hepatitis coinfection, no AIDS defining illness, and current CD4 200 cells per μL
6-12 85.6 73.4 61.2 54.1 49.0 45.1 32.9 20.7 13.6 8.5 4.6 -7.6 -14.7
12-18 64.1 51.9 39.7 32.6 27.5 23.6 11.4 -0.8 -7.9 -13.0 -16.9 -29.1 -36.2
18-24 59.8 47.6 35.4 28.3 23.2 19.3 7.1 -5.1 -12.2 -17.3 -21.2 -33.4 -40.5
24+ 26.5 14.3 2.1 -5.0 -10.1 -14.0 -26.2 -38.4 -45.5 -50.6 -54.5 -66.7 -73.8
Patient 2, 30 years old, coinfected with hepatitis, no AIDS defining illness, and current CD4 200 cells per μL
6-12 67.9 55.7 43.5 36.4 31.3 27.4 15.2 3.0 -4.1 -9.2 -13.1 -25.3 -32.4
12-18 46.4 34.2 22.0 14.9 9.8 5.9 -6.3 -18.5 -25.6 -30.7 -34.6 -46.8 -53.9
18-24 42.1 29.9 17.7 10.6 5.5 1.6 -10.6 -22.8 -29.9 -35.0 -38.9 -51.1 -58.2
24+ 8.8 -3.4 -15.6 -22.7 -27.8 -31.7 -43.9 -56.1 -63.2 -68.3 -72.2 -84.4 -91.5
-100
-80
-60
-40
-20
0
20
40
60
80
100 CD4 slope (cells/μL per year)
6~12 month
since initiation
12~18 month
since initiation
18~24 month
since initiation
24+ month
since initiation
Patient 1, 30 years old, no hepatitis coinfection, no AIDS defining illness, and current CD4 200 cells/μL
 20 cells/μL per year
 - 20 cells/μL per year
-100
-80
-60
-40
-20
0
20
40
60
80
100 CD4 slope (cells/μL per year)
6~12 month
since initiation
12~18 month
since initiation
18~24 month
since initiation
24+ month
since initiation
Patient 2, 30 years old, coinfected with hepatitis, no AIDS defining illness, and current CD4 200 cells/μL
 20 cells/μL per year
 - 20 cells/μL per year
HIV VL (copies/mL) 
 500  1 000  2 000  3 000  4 000  5 000  10 000  20 000  30 000  40 000  50 000   100 000  150 000
HIV VL (copies/mL) 
 500  1 000  2 000  3 000  4 000  5 000  10 000  20 000  30 000  40 000  50 000   100 000  150 000
Figure 2 Estimated CD4 slope (cells/μL/year) by duration of treatment and HIV VL.
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HIV VL tests, the CD4 count slope was associated with
age, concurrent CD4 count and HIV VL, disease stage,
hepatitis coinfection and time since cART initiation.
After cART initiation, CD4 counts continued to increase
even when the concurrent HIV VL was detectable.
However, HIV VL needed to be controlled at a lower
level to maintain a positive CD4 count slope when
cART continues at later stages, particularly from
6 months to more than 24 months after cART initiation.
The inverse relationship between age and CD4 restora-
tion has been reported in previous studies. In these stu-
dies younger age was associated with more rapid CD4
recovery and was associated with preserved thymic func-
tion [7,13-15]. The increase in CD4 slope after TB diag-
nosis, compared to CDC category A illness, might seem
counterintuitive. This might be simply due to the
increased total lymphocytes during active infections. The
increase could also be the short-term response due to the
increased adherence to cART [16,17] and introduction of
treatment for TB or other ADI [18,19].
Studies have shown that neither HBV nor HCV coin-
fection influence virological response to cART [20-22].
However, in terms of immunological response, the
results were mixed [20,21,23-25]. Law et al observed in
HIV-infected patients with HBV or HCV an initially
delayed CD4 count recovery at week four after HAART
treatment, but at week 48 the CD4 count increase was
similar to the patients only infected with HIV [26].
These studies examine the absolute CD4 count rather
than the trend since cART initiation. A decrease in CD4
count slope of less than 20 cells might not be clinically
significant in the early phase of cART, but from our
estimates (Table 3), it does have a significant impact on
whether the CD4 count slope decreased after longer
durations of cART. For example, the patient with no
hepatitis co-infection would continue to have a CD4
count increase over 20 cells/μL more than 24 months
after cART initiation even the concurrent HIV VL is
above 500 copies/mL. If this patient is co-infected with
hepatitis and on cART for more than 24 months, the
Table 4 Sensitivity analyses of the CD4 count slope.
Final model Initial treatment, before
any class change or stop
for more than 30 days
Initial NNRTI-based
regimen, before change
or stop for more than 30
days
Including patients with 4
or more CD4 slopes
endpoints
Difference* (95% CI) Difference* (95% CI) Difference* (95% CI) Difference* (95% CI)
Observations
= 10899
Observations
= 6697
Observations
= 4058
Observations
= 9826
Patients =
1676
Patients =
1353
Patients =
863
Patients =
1079
Current age, per 10 yrs
older
per unit -4.8 (-8.6, -1.0) -4.0 (-9.0, 1.0) -2.4 (-9.2, 4.4) -4.3 (-8.4, -0.2)
Concurrent viral load, per
log10 copies per mL
higher
per unit -40.5 (-48.4, -32.6) -43.4 (-58.5, -28.4) -45.1 (-68.0, -22.2) -39.5 (-48.1, -30.9)
Concurrent CD4 per 100
per μL higher
per unit 1.9 (0.2, 3.7) 3.4 (1.0, 5.7) 4.1 (0.9, 7.3) 1.9 (0.0, 3.8)
Disease stage
CDC Category A* 0.0 0.0 0.0 0.0
TB and/or other ADI 26.3 (15.6, 37.0) 29.9 (16.1, 43.7) 29.9 (13.9, 45.9) 26.4 (14.6, 38.1)
Non-TB ADI(s) 12.0 (2.5, 21.4) 16.4 (3.4, 29.4) 16.3 (-1.2, 33.9) 11.2 (0.9, 21.6)
Hepatitis B or C
coinfection
No* 0.0 0.0 0.0 0.0
Yes -17.7 (-29.7, -5.7) -17.5 (-33.1, -2.0) -19.8 (-39.6, 0.0) -18.7 (-31.9, -5.5)
Time since ART initiation
> 6 to ≤ 12 months* 0.0 0.0 0.0 0.0
> 12 to ≤ 18 months -21.5 (-37.8, -5.2) -29.4 (-48.2, -10.6) -16.3 (-40.9, 8.3) -19.6 (-37.8, -1.4)
> 18 to ≤ 24 months -25.8 (-42.0, -9.7) -32.8 (-51.9, -13.7) -13.9 (-38.8, 10.9) -25.8 (-43.6, -7.9)
> 24 or more months -59.1 (-71.7, -46.5) -65.6 (-80.7, -50.5) -55.4 (-75.3, -35.5) -59.1 (-73.1, -45.0)
Constant 205.5 (174.4, 236.6) 207.2 (157.7, 256.6) 192.8 (121.4, 264.2) 200.6 (166.6, 234.6)
* Difference were compared with the first category of each categorical variable
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CD4 count slope is below 20 cells/μL even the concur-
rent HIV VL is 500 copies/mL.
The PLATO study [7] reported that in patients experi-
encing triple class failure, treatment regimens that main-
tain the VL below 10 000 copies/mL or at least provide
1.5 log10 copies/mL suppression below the off-treatment
value do not seem to be associated with appreciable
CD4-cell-count decline. In a combined analysis between
Asian and Australian patients infected HIV, Egger et al
[14] reported a three-way interaction between the time
since cART, baseline CD4 and post-cART HIV VL and
estimated that for patients with intermittent HIV viral
suppression (below 400 copies/mL), the mean absolute
CD4 count begins to decrease or plateau after 4 years of
cART. These studies and our findings show that after
cART initiation, mean CD4 count slope can continued to
increase even when the concurrent HIV VL is detectable.
While Egger et al introduced the effect of time in the
equation of long term patterns of CD4 response, the
results from this analysis further added that the concur-
rent HIV VL level is a significant factor in determining
the trend of CD4 after cART.
Using data from EuroSIDA, Mocroft et al [8] reported
that CD4 did not significantly decrease even HIV VL
exceeded 10 000 copies/mL in patients treated with
regimen containing a boosted protease inhibitor. Drug
class and cART containing abacavir was also included in
the analysis, however, none remained significant in the
final model. This might be due to three reasons: first,
the paper by Mocroft et al analysed data from Euro-
SIDA where the predominant cART regimen was PI-
based (46% non-boosted, 23% boosted PI). TAHOD
recruits patients from the Asia Pacific region, with
NNRTI-based regimen as the most common initial
cART (63%, 15% non-boosted and 20% boosted PI). In
addition, abacavir was not frequently used in TAHOD;
second, the patients who received PI- or NNRTI-based
cART as initial regimen might be different between
EuroSIDA and TAHOD, which could result in a differ-
ent recovery pattern of the immune system; three, as
suggested by Mocroft et al, larger studies with increased
power are needed. Nonetheless, our study provided
complementary evidence in patients from Asia Pacific
region that CD4 counts continues to increase even
when the concurrent HIV VL was detectable.
Similar to other studies [11-13], our data showed a
two-phase CD4 count response with a high CD4 count
slope in the first six months after treatment initiation
followed by a lower slope. The only factor in the final
multivariate model (Table 2) that could be modified and
had a significant impact on CD4 count slope was the
concurrent HIV VL, which is a 40 CD4 cells decrease
for every 1 log10 HIV VL increase. From our estimation
(Table 3), the CD4 count continues to increase with
HIV VL up to 20 000 copies/mL during 6-12 months
after cART initiation. However, the HIV VL has to be
controlled below 5 000, 4 000 and 500 copies/mL for
the CD4 count slope to reach a safe level above
20 cells/μL/year during 12-18, 18-24, and beyond
24 months after cART initiation.
In many countries in Asia, second-line cART is not
widely accessible [3-6]. Several studies reported sustain-
able CD4 count increases in patients with virological
failure but remained on the same failing cART [27-29].
Our results suggest that patients with detectable but
modest VL may continue their failing cART regimen
without increasing their immune deficiency and the risk
of poor clinical outcomes over the short term. This is in
agreement with the US treatment guideline [2], which
recommended adherence assessment, repeated HIV VL
tests to rule out “blips” [30], and genotypic tests to
detect drug resistant mutations before considering treat-
ment switch. The recent 2009 revision of the WHO
antiretroviral therapy guidelines [31] recommended
adherence assessment, repeated HIV VL test, and switch
only when HIV VL remains more than 5 000 copies/
mL. If HIV VL monitoring is available, switch to sec-
ond-line cART should be done as soon as possible when
treatment failure is established. However, in many coun-
tries in Asia, especially those developing countries, fre-
quent HIV VL monitoring and genotypic tests are
beyond the limited resource for HIV treatment and care
[32]. If CD4 count is the only way for monitoring treat-
ment response, the result of this analysis showed that a
patient can have a considerable duration of virological
failure without meeting CD4 criteria recommended by
WHO for switch of ART to second line. In addition, the
effect of delaying switching treatment on longer term
outcomes through the possible development of HIV-
drug resistance that could compromise the efficacy of
later cART regimens remains uncertain.
Limitations
Several limitations should be considered in interpreting
the results in this paper. First, TAHOD participating
sites are generally urban referral centres, and each site
recruits 200-300 patients who are considered by local
clinicians to have a reasonably good prospect of long-
term follow-up. Hence TAHOD patients, and their
treatment, are not representative of all HIV-infected
patients in the Asia and Pacific region. Second, we do
not have data on adherence and treatment against TB
and other ADI. Finally, a more thorough analysis would
include the survival outcome. However, because of the
limited number and follow-up of patients who were fail-
ing virologically, this analysis is currently underpowered.
Further analyses will be considered with longer duration
of follow-up.
Zhou et al. BMC Infectious Diseases 2010, 10:361
http://www.biomedcentral.com/1471-2334/10/361
Page 8 of 10
Conclusion
The analyses suggest that after cART initiation, mean
CD4 slope can continue to increase even when the con-
current HIV VL is detectable. HIV VL needed to be
controlled at a lower level to maintain a positive CD4
slope beyond 2 years of cART. However, the effect on
longer term outcomes through the possible development
of HIV-drug resistance remains uncertain.
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